ReviewCancer cell international2025
Exploring the role of miR-221/222 in gastrointestinal cancers: implications for innovative therapeutic strategies.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs, also known as miRNAs, have a substantial part in regulating different essential cellular functions through post-transcriptional mechanisms. When they are not properly regulated, they can cause development and growth of numerous human illnesses, such as cancer. The MiR-221/222 family of genes is commonly disrupted in various forms of gastrointestinal (GI) cancer. Gastrointestinal cancers are the most commonly occurring cancerous growths across the world, with a significant number of cases and fatalities. Despite many improvements in the care of gastrointestinal cancer, such as the use of chemotherapy and immunotherapy protocols, a considerable proportion of individuals still exhibit a subpar reaction to treatment, leading to unsatisfactory rates of survival. IFinding new therapeutic targets is essential to improving treatment results for people with GI cancer. An increasing amount of recent research indicates that miR-221/222 is highly engaged in the growth of GI cancer. This article thoroughly examines the abnormal levels of miR-221/222 in diverse GI cancers like colon cancer, pancreatic cancer, gastric cancer, esophageal carcinoma, and hepatocellular carcinoma. Additionally, it summarises the latest knowledge regarding the functions and target genes of miR-221/222, and its mechanism of action in GI cancers. This information may pave the way for the advancement of innovative treatment strategies for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.